Minerva Neurosciences (NERV) Interest & Investment Income (2013 - 2026)
Minerva Neurosciences' (NERV) quarterly Interest & Investment Income came in at $629602.0 in Q1 2026, up 297.76% YoY from $158288.0 in Q1 2025, and up 15.2% on a QoQ basis from $546523.0 in Q4 2025.
Powered by 
Analysis
Minerva Neurosciences (NERV) Interest & Investment Income (2013 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Interest & Investment Income data on file, last reported at $629602.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 297.76% year-over-year to $629602.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 32.32% YoY) and the FY2025 annual result came in at $948122.0, down 25.48% from the prior year.
- Interest & Investment Income rose to $629602.0 in Q1 2026, from $546523.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $629602.0 in Q1 2026 to a low of $7417.0 in Q1 2022.
- A 5-year average of $284966.4 and a median of $313967.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 7941.69% — and 2025, when it tumbled 66.03%.
- Tracing NERV's Interest & Investment Income over 5 years: stood at $297060.0 in 2022, then climbed by 20.81% to $358883.0 in 2023, then sank by 33.2% to $239724.0 in 2024, then surged by 127.98% to $546523.0 in 2025, then advanced by 15.2% to $629602.0 in 2026.
- The last three Interest & Investment Income figures came in at $629602.0 (Q1 2026), $546523.0 (Q4 2025), and $106640.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | 569,591.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 569,591.00 |
| Mar 31, 2026 | 629,602.00 |
| Dec 31, 2025 | 546,523.00 |
| Sep 30, 2025 | 106,640.00 |
| Jun 30, 2025 | 136,671.00 |
| Mar 31, 2025 | 158,288.00 |
| Dec 31, 2024 | 239,724.00 |
| Sep 30, 2024 | 313,967.00 |
| Jun 30, 2024 | 360,755.00 |
| Mar 31, 2024 | 357,908.00 |
| Dec 31, 2023 | 358,883.00 |
| Sep 30, 2023 | 348,681.00 |
| Jun 30, 2023 | 365,623.00 |
| Mar 31, 2023 | 364,218.00 |
| Dec 31, 2022 | 297,060.00 |
| Sep 30, 2022 | 180,091.00 |
| Jun 30, 2022 | 72,378.00 |
| Mar 31, 2022 | 7,417.00 |
| Dec 31, 2021 | 3,694.00 |
| Sep 30, 2021 | 4,156.00 |